Deals

plan B fail reroute road path trail miss
Biotech

Pulmatrix picked for reverse merger with anti-aging biotech

Pulmatrix may have been discarded by Cullgen, but the inhaled therapy biotech’s Nasdaq listing has caught the attention of another company.
James Waldron Mar 26, 2026 10:12am
dollar sign pipeline

Biopharma funding fell 20% in 2025: IQVIA

Mar 26, 2026 6:01am
Sea gull

Merck flies toward CML asset with $6.7B Terns acquisition

Mar 25, 2026 10:28am
Large group of people seen from above gathered together in the shape of medicine cross symbol

Icon, Advarra team up to optimize trials, expand access

Mar 24, 2026 4:52pm
Comfy bed sitting on pink clouds

Shionogi pays Apnimed $100M for sleep disorder joint venture

Mar 24, 2026 9:20am
Focus magnify target strategy

Merck hands over $20M in IBD target deal with Quotient

Mar 24, 2026 6:00am